Amgen Reports Mixed Q1 2026 Results Amid Pipeline Advances and Regulatory Challenges
Event summary
- Amgen reports 6% revenue growth to $8.6B in Q1 2026, with 16 brands achieving double-digit growth.
- GAAP EPS increased 4% to $3.34, while non-GAAP EPS rose 5% to $5.15.
- FDA proposes withdrawal of TAVNEOS approval due to effectiveness concerns.
- MariTide pipeline advances with multiple Phase 3 studies ongoing.
- Free cash flow increased to $1.5B, up from $1B in Q1 2025.
The big picture
Amgen's Q1 2026 results highlight the company's ability to grow through patent expirations and increased competition, driven by a strong pipeline and strategic acquisitions. However, regulatory challenges, particularly with TAVNEOS, pose significant risks that could impact future performance. The company's focus on innovative therapies like MariTide underscores its commitment to long-term growth in the biotechnology and pharmaceutical sectors.
What we're watching
- Regulatory Risk
- The FDA's proposal to withdraw TAVNEOS approval could impact Amgen's revenue and regulatory strategy.
- Pipeline Progress
- The advancement of MariTide through multiple Phase 3 studies will be critical for Amgen's long-term growth prospects.
- Market Dynamics
- The ability to sustain double-digit growth across multiple brands amid patent expirations and increased competition.
Related topics